Patients Referred to the Chronic Pain Unit for Palliative Treatment With Ozone Therapy Between 2022 and 2025
Recruiting · NCT05417737 · Observational (researchers observe without assigning treatment)
View the official record on ClinicalTrials.gov →Interventions studied
Ozone therapy
What this trial is about
The main objective of this study is to analyze the impact on the health-related quality of life of patients with refractory symptoms, who have been referred to the HUGCDN Chronic Pain Unit for adjuvant palliative treatment with ozone therapy between June-2022 and December-2025
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Adults \> = 18 years old.
- Patients submitted to the Chronic Pain Unit of the Hospital Universitario de Gran Canaria Dr. Negrín for symptomatic/palliative treatment with ozone therapy because conventional treatment does not exist, it has been unsuccessful, or it is associated with high risk or high morbidity.
- After evaluation of symptoms and patients, it exists a potential benefit of adding ozone treatment to the current treatment.
- Patients have no contraindications for ozone treatment.
- Patients have signed and dated the informed consent for the compassionated ozone treatment and the specific informed consent for this study
Exclusion criteria
- Age \< 18 years old.
- Psychiatric illness or social situations that would limit compliance with study requirements.
- Those who are incapable to fill in the scales used to measure variables.
- Hemodynamically or clinically unstable patients or uncontrolled severe illness.
- Uncontrolled cancer disease requiring chemotherapy treatment.
- Life expectancy \< 6 months
- Contraindication or disability or to attend scheduled treatments.
- Known allergy to ozone.
- Pregnancy at the time of enrollment (for systemic ozone therapy). 10 Hemochromatosis (for systemic ozone therapy).
- \. Known significant glucose-6-phosphate dehydrogenase deficiency (favism, acute hemolytic anemia) (for systemic ozone therapy).
- \. Patients who do not meet all the inclusion criteria
Where it is running
2 locations listed.
- Dr. Negrín University Hospital - Las Palmas, Las Palmas, Spain
- Dr. Negrín University Hospital - Las Palmas, Las Palmas, Spain